The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ESH MM 2021 | Evolution of multiple myeloma treatment in Norway
Fredrik Schjesvold, MD, PhD, Oslo University Hospital, Oslo, Norway, outlines the evolution of multiple myeloma treatment in Norway. Dr Schjesvold highlights use of the lenalidomide, bortezomib and dexamethasone triplet in the first-line setting, as well as discussing the uptake of various diagnostic tools to improve multiple myeloma treatment. This interview took place during the 3rd European Society of Hematology How to Diagnose and Treat Multiple Myeloma (ESH MM) 2021 congress.
